Thu, Mar. 5, 5:06 PM| Comment!
Nov. 10, 2014, 5:18 PM| Comment!
Aug. 13, 2014, 11:49 AM
Aug. 12, 2014, 4:52 PM| Comment!
May. 12, 2014, 8:57 AM| Comment!
Mar. 6, 2014, 7:14 AM| Comment!
Nov. 14, 2013, 8:14 AM
Aug. 12, 2013, 6:38 PM
- Tetraphase Pharmaceuticals (TTPH) posts its first earnings release after its IPO debut in April, coming in mixed for the quarter.
- Q2 revenue beat, but results came in shy of estimates on a per share basis.
- Revenues for the period consisted of contract and grant revenue under three U.S. government awards for the development of compounds as potential counter measures for treating bacterial bio-threat pathogens through subcontracts and a sub-award from its collaborator, CUBRC Incorporated.
- R&D expenses grew, largely due to an increase in expenses related to activities under our subcontracts with CUBRC, as well as an increase in clinical costs associated with the Phase 3 program and the Phase 1 oral PK program for eravacycline.
- Shares -1% AH.
Aug. 12, 2013, 5:37 PM| Comment!
TTPH vs. ETF Alternatives
Tetraphase Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in creating antibiotics for serious and life-threatening multidrug-resistant infections. Its product candidate eravacycline is a fully synthetic tetracycline derivative.
Other News & PR